A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Inclusion Criteria

• Receiving prophylaxis for or with a confirmed or suspected infection with Gram-positive bacteria and receiving concurrent antibiotic treatment with Gram-positive antibacterial activity;
• Weight >5th percentile and <95th percentile based on age;
• Stable condition as determined from medical history, physical examination, minimally 5-lead electrocardiogram (ECG), vital signs, and clinical laboratory evaluations;
• Females must be premenarchal, abstinent, or practicing an effective method of birth control;

Exclusion Criteria

• History of seizures, other than febrile seizures, clinically significant cardiac arrhythmia, cystic fibrosis, moderate or severe renal impairment, or any physical condition that could interfere with the study results;
• Recent (3 month) history or current infection with viral hepatitis or other significant hepatic disease;
• History of drug allergy or hypersensitivity to oxazolidinones;
• Pregnant or breast feeding;
• Significant blood loss within 60 days prior to study start;
• Any acute or chronic condition that would limit the participant's ability to complete and/or participate in this clinical study.
• Treatment with investigational medicinal product within 30 days before the infusion/dose of study drug.
• Oral administration of methotrexate, topotecan, irinotecan or rosuvastatin, during administration of oral study drug. Administration during the follow-up period is allowed, as is administration during treatment with IV study drug.
• Use of monoamine oxidase inhibitors or serotonergic agents including tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin 5 hydroxytryptamine receptor agonists (triptans), meperidine, or buspirone within,14 days prior to study, or planned use while on study.